PHOTOCURE®

THE BLADDER CANCER COMPANY

Photocure ASA - Share option grant

Oslo, Norway, 29 July 2026 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

A total of 265,000 share options, equal to 0.98% of total shares issued in the Company, were granted to the executive leadership team at an exercise price at NOK 63,93 per share (the "ELT Options"). The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price.

The ELT Options are granted in accordance with Photocure's long term incentive program and the Company's guidelines for remuneration of senior executives (the "Guidelines"), as approved by Photocure's annual general meeting held 26 June 2026. The share option program and properties of the options are further described in the Guidelines.

The following ELT Options were granted to primary insiders:

- Daniel Schneider, President and Chief Executive Officer, 100,000 options
- Geoffrey Coy, Vice President and General Manager North America, 40,000 options
- Jane Healy, Vice President and General Manager Europe, 50,000 options
- Anders Neijber, Chief Medical Officer, Global Medical Affairs and Clinical Development and R&D, 40,000 options
- Anja Gossens-Von Der Heidt, Head of Global Human Resources, 35,000 options

Primary insider notifications pursuant to the market abuse regulation article 19 are attached.

For further information, please contact:

Priyam Shah
Vice President Investor Relations
Tel : +17176815072
Email: priyam.shah@photocure.com

About Photocure ASA

Photocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com/news